---
title: 'Prevention of Stroke in Intracerebral Haemorrhage Survivors with Atrial Fibrillation:
  Rationale and Design for PRESTIGE-AF Trial'
date: '2024-12-31'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39740761/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250101170753&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Adequate secondary prevention in survivors of intracerebral hemorrhage
  (ICH) who also have atrial fibrillation (AF) is a long-standing clinical dilemma
  because these patients are at increased risk of recurrent ICH as well as of ischemic
  stroke. The efficacy and safety of oral anticoagulation, the standard preventive
  medication for ischemic stroke patients with AF, in ICH patients with AF are uncertain.
  PRESTIGE-AF is an international, phase 3b, multi-center, randomized, open, blinded
  ...
disable_comments: true
---
Adequate secondary prevention in survivors of intracerebral hemorrhage (ICH) who also have atrial fibrillation (AF) is a long-standing clinical dilemma because these patients are at increased risk of recurrent ICH as well as of ischemic stroke. The efficacy and safety of oral anticoagulation, the standard preventive medication for ischemic stroke patients with AF, in ICH patients with AF are uncertain. PRESTIGE-AF is an international, phase 3b, multi-center, randomized, open, blinded ...